News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Covidien plc (COV) Announces CE Mark Approval For Puritan Bennett™ 980 Ventilator


3/3/2014 6:51:53 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Covidien Announces CE Mark Approval for Puritan Bennett™ 980 Ventilator

DUBLIN, Ireland--(BUSINESS WIRE)--Covidien plc (NYSE: COV), a leading global provider of healthcare products and recognized innovator in patient monitoring and respiratory care devices, today announced its Puritan Bennett™ 980 ventilator has received European Economic Area (EEA) CE Mark approval.

The new acute care ventilator from Covidien—designed to be simple, safe and smart—helps enable patients, from neonatal to adult, to breathe more naturally† through some of the most innovative breath technology available.

“We are excited to introduce our next-generation acute ventilation platform, the Puritan Bennett 980 ventilator,” said Cristiano Franzi, president, Europe, Covidien. “Building on Covidien’s strong legacy of innovation, the Puritan Bennett 980 ventilator will provide clinicians with a simple, safe and smart way to care for patients.”

The Puritan Bennett 980 ventilator system is for patients ranging from neonatal to adult. The ventilator system was also approved for commercial distribution in the U.S., Japan and Canada and will be available for sale in those countries as well as the EEA in the coming months. For more information about the Puritan Bennett 980 ventilator, please visit www.covidien.com/PB980.

†Compared to conventional mechanical ventilation

ABOUT COVIDIEN
Covidien is a leading global healthcare products company that creates innovative medical solutions for better patient outcomes and delivers value through clinical leadership and excellence. Covidien develops, manufactures and sells a diverse range of industry-leading medical device and supply products. With 2013 revenue of $10.2 billion, Covidien has more than 38,000 employees worldwide in more than 70 countries, and its products are sold in over 150 countries. Please visit www.covidien.com to learn more about our business.

Contacts

Covidien
Rhonda Luniak, 303-406-8743
Vice President
R&MS Communications
rhonda.luniak@covidien.com
or
Lisa Clemence, 508-452-4375
Director
Corporate Communications
lisa.clemence@covidien.com
or
Coleman Lannum, CFA, 508-452-4343
Vice President
Investor Relations
cole.lannum@covidien.com
or
Todd Carpenter, 508-452-4363
Senior Director
Investor Relations
todd.carpenter@covidien.com

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES